Antiapoptotic drugs: A therapautic strategy for the prevention of neurodegenerative diseases

Current Pharmaceutical Design

Volumn 17, Issue 3, 2011, Pages 230-245

  Sureda, Francesc X ^a   Junyent, Felix ^a,b   Verdaguer, Ester ^b   Auladell, Carme ^b   Pelegri, Carme ^b   Vilaplana, Jordi ^b   Folch, Jaume ^a   Canudas, Anna Maria ^b   Zarate, Carlos Beas ^c   Pallàs, Mercè ^b   Camins, Antoni ^b  

^a UNIVERSITAT ROVIRA I VIRGILI   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c UNIVERSITY OF GUADALAJARA   (Mexico)

Author keywords

Alzheimer's disease; Apoptosis; Cyclin dependent kinases; Glutamate receptors; Neuronal cell death; Neuroprotective drugs. apoptosis; Parkinson's disease

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; 2 AMINOTHIAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; AR A014418; ATORVASTATIN; CARNOSINE; CEP 1347; CHOLINESTERASE INHIBITOR; CYSTEINE PROTEINASE INHIBITOR; FENOPROFEN; FLAVOPIRIDOL; FLURBIPROFEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBUPROFEN; IDEBENONE; INDOMETACIN; LEVODOPA; MELATONIN; MEVINOLIN; MINOCYCLINE; PD 150606; PIOGLITAZONE; RESVERATROL; ROSCOVITINE; ROSIGLITAZONE; SB41528; SIMVASTATIN; TROGLITAZONE; UBIDECARENONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; [1 [(1 FORMYL 2 PHENYLETHYL)CARBAMOYL] 2 METHYLPROPYL]CARBAMIC ACID BENZYL ESTER;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT ACTIVITY; APOPTOSIS; BLOOD BRAIN BARRIER; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; COGNITION; DEGENERATIVE DISEASE; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; DNA DAMAGE; DNA SYNTHESIS; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; ENZYME ACTIVATION; EXCITOTOXICITY; GENE THERAPY; HUMAN; HUNTINGTON CHOREA; MITOCHONDRIAL DNA DISORDER; MITOCHONDRIAL PERMEABILITY; MULTIINFARCT DEMENTIA; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NEUROMODULATION; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; STROKE; UNSPECIFIED SIDE EFFECT;

EID: 79958199462     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211795049732     Document Type: Review

References (210)

1. Middleton LE, Yaffe K. Promising strategies for the prevention ofdementia. Arch Neurol. 2009; 66: 1210-5.
2. Maccioni R.B., Munoz J.P., Barbeito L. The molecular bases of Alzheimer's disease and other neurodegenerative disorders. ArchMed Res 2001; 32: 367-81.
3. Ribe EM, Serrano-Saiz E, Akpan N, Troy CM. Mechanisms ofneuronal death in disease: defining the models and the players. Biochem J 2008; 415: 165-82.
4. Poewe W, Antonini A, Zijlmans JC, Burkhard PR, Vingerhoets F. Levodopa in the treatment of Parkinson's disease: an old drug stillgoing strong. Clin Interv Aging 2010; 5: 229-38.
5. Kaduszkiewicz H, Zimmermann T, Beck-Bornholdt HP, van denBussche H. Cholinesterase inhibitors for patients with Alzheimer'sdisease: systematic review of randomised clinical trials. BMJ 2005;331: 321-7.
6. Johannsen P. Long-term cholinesterase inhibitor treatment ofAlzheimer's disease. CNS Drugs 2004; 18: 757-68.
7. Caroppi P, Sinibaldi F, Fiorucci L, Santucci R. Apoptosis andhuman diseases: mitochondrion damage and lethal role of releasedcytochrome C as proapoptotic protein. Curr Med Chem 2009; 16:4058-65.
8. Neymotin A, Petri S, Calingasan NY, et al. Lenalidomide (Revlimid)administration at symptom onset is neuroprotective in amouse model of amyotrophic lateral sclerosis. Exp Neurol 2009;220: 191-7.
9. ALu PH, Edland SD, Teng E, Tingus K, Petersen RC, Cummings JL; Alzheimer's Disease Cooperative Study Group. Donepezil de lays progression to AD in MCI subjects with depressive symptoms.Neurology 2009; 72: 2115-21.
10. Lipton SA. Paradigm shift in neuroprotection by NMDA receptorblockade: memantine and beyond. Nat Rev Drug Discov 2006; 5:160-70.
11. Marques SC, Oliveira CR, Outeiro TF, Pereira CM. Alzheimer'sdisease: the quest to understand complexity. J Alzheimers Dis 2010; 21: 373-83.
12. de Oliveira RM, Pais TF, Outeiro TF. Sirtuins: common targets inaging and in neurodegeneration. Curr Drug Targets 2010; 11: 1270-80.
13. Stanfel MN, Shamieh LS, Kaeberlein M, Kennedy BK. The TORpathway comes of age. Biochim Biophys Acta 2009; 1790: 1067-1074.
14. Butterfield DA, Bader Lange ML, Sultana R. Involvements of thelipid peroxidation product, HNE, in the pathogenesis and progressionof Alzheimer's disease. Biochim Biophys Acta 2010; 1801:924-9.
15. Allen JW, Eldadah BA, Huang X, Knoblach SM, Faden AI. Multiplecaspases are involved in beta-amyloid-induced neuronal apoptosis. J Neurosci Res 2001; 65: 45-53.
16. Battaglia F, Trinchese F, Liu S, Walter S, Nixon RA, Arancio O.Calpain inhibitors, a treatment for Alzheimer's disease: positionpaper. J Mol Neurosci 2003; 20: 357-62.
17. Boland B, Campbell V. beta-Amyloid (1-40)-induced apoptosis ofcultured cortical neurones involves calpain-mediated cleavage ofpoly-Alzheimer's disease P-ribose polymerase. Neurobiol Aging 2003; 24: 179-86.
18. Selenica ML, Jensen HS, Larsen AK, et al. Efficacy of smallmoleculeglycogen synthase kinase-3 inhibitors in the postnatal ratmodel of tau hyperphosphorylation. Br J Pharmacol. 2007; 152:959-79.
19. Lim AC, Qi RZ. Cyclin-dependent kinases in neural developmentand degeneration. J Alzheimers Dis 2003; 5: 329-35.
20. Wang W, Yang Y, Ying C, et al. Inhibition of glycogen synthasekinase-3beta protects dopaminergic neurons from MPTP toxicity. Neuropharmacology 2007; 52: 1678-84.
21. Koh SH, Kim Y, Kim HY, Hwang S, Lee CH, Kim SH. Inhibitionof glycogen synthase kinase-3 suppresses the onset of symptomsand disease progression of G93A-SOD1 mouse model of ALS. ExpNeurol 2007; 205: 336-46
22. Lim AC, Qi RZ. Cyclin-dependent kinases in neural developmentand degeneration. J Alzheimers Dis 2003; 5: 329-35.
23. Lee HG, Casadesus G, Zhu X, et al. Cell cycle re-entry mediatedneurodegeneration and its treatment role in the pathogenesis ofAlzheimer's disease. Neurochem Int 2009; 54: 84-8.
24. Reed, J.C. Apoptosis-regulating proteins as targets for drug discovery.Trends Mol Med 2001; 7: 314-9
25. Kroemer G, Galluzzi L, Brenner C. Mitochondrial membranepermeabilization in cell death. Physiol Rev 2007; 87: 99-163.
26. Galluzzi L, Blomgren K, Kroemer G. Mitochondrial membranepermeabilization in neuronal injury. Nat Rev Neurosci 2009; 10:481-94.
27. Hisatomi T, Ishibashi T, Miller JW, Kroemer G. Pharmacologicalinhibition of mitochondrial membrane permeabilization for neuroprotection. Exp Neurol 2009; 218: 347-52.
28. Van Loo G., Saelens X., van Gurp M, MacFarlane M, Martin SJ, Vandenabeele P. The role of mitochondrial factors in apoptosis: aRussian roulette with more than one bullet. Cell Death Diff 2002;9: 1031-42.
29. Nicotera, P., Leist, M. Energy supply and the shape of death inneurons and lymphoid cells. Cell Death Differ 1997; 4: 435-42.
30. Kerr, J.F.R. History of the events leading to the formulation of theapoptosis concept. Toxicology 2002; 181-182: 471-4.
31. Friedlander, R.M. Apoptosis and caspases in neurodegenerativediseases. New England J Med 2003; 348: 1365-75.
32. D'Mello SR, Chin PC. Treating neurodegenerative conditionsthrough the understanding of neuronal apoptosis. Curr Drug TargetsCNS Neurol Disord 2005; 4: 3-23.
33. Stavrovskaya IG, Kristal BS. The powerhouse takes control of thecell: is the mitochondrial permeability transition a viable therapeutictarget against neuronal dysfunction and death? Free Radic BiolMed 2005; 38: 687-97.
34. Rostovtseva TK, Tan W, Colombini M. On the role of VDAC inapoptosis: fact and fiction. J Bioenerg Biomembr 2005; 37: 129-42.
35. Troy, C.M., Salvesen, G.S. Caspases on the brain. J Neurosci Res 2002; 69: 145-50.
36. Rohn TT, Rissman RA, Davis MC, Kim YE, Cotman CW, Head E. Caspase-9 activation and caspase cleavage of tau in the Alzheimer'sdisease brain. Neurobiol Dis 2002; 11: 341-54.
37. Takuma H, Tomiyama T, Kuida K, Mori H. Amyloid beta peptideinducedcerebral neuronal loss is mediated by caspase-3 in vivo. JNeuropathol Exp Neurol 2004; 63: 255-61.
38. Takuma K, Yan SS, Stern DM, Yamada K. Mitochondrial dysfunction,endoplasmic reticulum stress, and apoptosis in Alzheimer'sdisease. J Pharmacol Sci 2005; 97: 312-16.
39. LeBlanc A, Liu H, Goodyer C, Bergeron C, Hammond J. Caspase-6 role in apoptosis of human neurons, amyloidogenesis, and Alzheimer'sdisease. J Biol Chem 1999; 274: 23426-36.
40. Galluzzi L, Maiuri MC, Vitale I, et al. Cell death modalities:classification and pathophysiological implications. Cell Death Differ 2007; 14: 1237-43.
41. Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med 2006; 12: 440-50.
42. Chipuk JE, Green DR. PUMA cooperates with direct activatorproteins to promote mitochondrial outer membrane permeabilizationand apoptosis. Cell Cycle 2009; 8: 2692-96.
43. Fletcher JI, Huang DC Controlling the cell death mediators Baxand Bak: puzzles and conundrums. Cell Cycle 2008; 7: 39-44.
44. Macleod MR, Ramage L, McGregor A, Seckl JR. ReducedNMDA-induced apoptosis in neurons lacking ataxia telangiectasiamutated protein. Neuroreport. 2003; 14: 215-17.
45. Shah RS, Lee HG, Xiongwei Z, Perry G, Smith MA, Castellani RJ.Current approaches in the treatment of Alzheimer's disease. BiomedPharmacother 2008; 62: 199-207.
46. Zhu X, Smith MA, Perry G, Aliev G. Mitochondrial failures inAlzheimer's disease. Am J Alzheimers Dis Other Demen 2004; 19:345-52.
47. Zhu X, Lee HG, Casadesus G, et al. Oxidative imbalance in Alzheimer'sdisease. Mol Neurobiol 2005; 31: 205-17.
48. Przedborski S, Ischiropoulos H. Reactive oxygen and nitrogenspecies: weapons of neuronal destruction in models of Parkinson'sdisease. Antioxid Redox Signal 2005; 7: 685-93.
49. Moreira PI, Smith MA, Zhu X, Santos MS, Oliveira CR, Perry G. Therapeutic potential of oxidant mechanisms in Alzheimer's disease. Expert Rev Neurother 2004; 4: 995-1004.
50. Aliev G, Obrenovich ME, Reddy VP, Shenk JC, Moreira PI, Nunomura A et al. Antioxidant therapy in Alzheimer's disease: theoryand practice. Mini Rev Med Chem 2008; 8: 1395-406.
51. Vina J, Lloret A, Orti R, Alonso D. Molecular bases of the treatment of Alzheimer's disease with antioxidants: prevention of oxidative stress. Mol Aspects Med 2004; 25: 117-23.
52. Wengreen HJ, Munger RG, Corcoran CD, et al. Antioxidant intake and cognitive function of elderly men and women: the Cache County Study. J Nutr Health Aging 2007; 11: 230-7
53. Hsiung GY, Feldman HH. Pharmacological treatment in moderateto-severe Alzheimer's disease. Expert Opin Pharmacother 2008; 9:2575-82.
54. Leon J, Acuña-Castroviejo D, Sainz RM, Mayo JC, Tan DX, Reiter RJ. Melatonin and mitochondrial function. Life Sci 2004; 75: 765-90.
55. Stvolinsky S, Antipin M, Meguro K, Sato T, Abe H, Boldyrev A. Effect of carnosine and its Trolox-modified derivatives on life spanof Drosophila melanogaster. Rejuvenation Res 2010; 13: 453-57.
56. Berman K, Brodaty H. Tocopherol (vitamin E) in Alzheimer'sdisease and other neurodegenerative disorders. CNS Drugs 2004;18: 807-25.
57. Lloret A, Badía MC, Mora NJ, Pallardó FV, Alonso MD, Viña J. Vitamin E paradox in Alzheimer's disease: it does not prevent lossof cognition and may even be detrimental. J Alzheimers Dis 2009;17: 143-49.
58. Petersen RC, Thomas RG, Grundman M, et al. Alzheimer's DiseaseCooperative Study Group. Vitamin E and donepezil for the treatmentof mild cognitive impairment. N Engl J Med 2005; 352:2379-88.
59. Munoz FJ, Sole M, Coma M. The protective role of vitamin E invascular amyloid beta-mediated damage. Subcell Biochem 2005;38: 147-65.
60. Luchsinger JA, Mayeux R. Dietary factors and Alzheimer's disease.Lancet Neurol 2004; 3: 579-87.
61. Zandi PP, Anthony JC, Khachaturian AS, et al. Reduced risk ofAlzheimer disease in users of antioxidant vitamin supplements: the Cache County Study. Arch Neurol 2004; 61: 82-8.
62. Battino M, Bompadre S, Leone L, et al. Coenzyme Q, Vitamin Eand Apo-E alleles in Alzheimer Disease. Biofactors 2003; 18: 277-81.
63. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the invivo evidence. Nat Rev Drug Discov 2006; 5: 493-506.
64. Pallàs M, Casadesús G, Smith MA, et al. Resveratrol and neurodegenerative diseases: activation of SIRT1 as the potential pathwaytowards neuroprotection. Curr Neurovasc Res 2009; 6: 70-81.
65. Knutson MD, Leeuwenburgh C. Resveratrol and novel potentactivators of SIRT1: effects on aging and age-related diseases. Nutr Rev 2008; 66: 591-6.
66. Orallo F. Trans-resveratrol: a magical elixir of eternal youth? Curr Med Chem 2008; 15: 1887-98.
67. Wang J, Ho L, Zhao Z, et al. Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease. FASEB J 2006; 20: 2313-20.
68. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, et al. SIRT1 deacetylase protects against neuro degeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 2007; 26: 3169-79.
69. Alvira D, Yeste-Velasco M, Folch J, et al. Comparative analysis of the effects of resveratrol in two apoptotic models: inhibition of complex I and potassium deprivation in cerebellar neurons. Neuroscience 2007; 147: 746-56.
70. Cardinali DP, Brusco LI, Liberczuk C, Furio AM. The use of melatonin in Alzheimer's disease. Neuro Endocrinol Lett 2002; 23Suppl 1: 20-3.
71. López A, García JA, Escames G, et al. Melatonin protects themitochondria from oxidative damage reducing oxygen consumption,membrane potential, and superoxide anion production. J Pineal Res 2009; 46: 188-98.
72. Carretero M, Escames G, López LC, et al. Long-term melaton in administration protects brain mitochondria from aging. J Pineal Res 2009; 47: 192-200.
73. Wang X. The antiapoptotic activity of melatonin in neuro degenerative diseases. CNS Neurosci Ther 2009; 15: 345-57.
74. Rodríguez MI, Escames G, López LC, et al. Improved mitochondrial function and increased life span after chronic melaton in treatment in senescent prone mice. Exp Gerontol 2008; 43: 749-56.
75. Singer C, Tractenberg RE, Kaye J, et al. A multicenter, placebo-controlled trial of melatonin for sleep disturbance in Alzheimer's disease. Sleep 2003; 26: 893-901.
76. Medeiros CA, Carvalhedo de Bruin PF, Lopes LA, et al. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study. J Neurol 2007; 254: 459-64.
77. Bordet R, Devos D, Brique S, et al. A study of circadian melatonin secretion pattern at different stages of Parkinson's disease. Clin Neuropharmacol 2003,26: 65-72.
78. Olcese JM, Cao C, Mori T, et al. Protection against cognitive deficits and markers of neuro-degeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J Pineal Res 2009; 47: 82-96.
79. Furio AM, Brusco LI, Cardinali DP. Possible therapeutic value of melatonin in mild cognitive impairment: a retrospective study. J Pineal Res 2007; 43: 404-9.
80. Boldyrev A, Fedorova T, Stepanova M, et al. Carnosine increases efficiency of DOPA therapy of Parkinson's disease. Rejuvenation Res 2008; 11: 988-94.
81. Hipkiss AR. Carnosine, diabetes and Alzheimer's disease. Expert Rev Neurother 2009; 9: 583-85.
82. Shults CW. Coenzyme Q10 in neurodegenerative diseases. Curr Med Chem 2003; 10: 1971-21.
83. Beal MF. Mitochondrial dysfunction and oxidative damage in Alzheimer's and Parkinson's diseases and coenzyme Q10 as a potential treatment. J Bioenerg Biomembr 2004; 36: 381-6.
84. Beal MF, Matthews RT, Tieleman A, Shults CW. Coenzyme Q10attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP)induced loss of striatal dopamine and dopaminergic axons in agedmice. Brain Res 1998; 783: 109-14.
85. Shults CW, Flint Beal M, Song D, Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp Neurol 2004; 188: 491-4.
86. Stamelou M, Reuss A, Pilatus U, et al. Short-term effects of coenzymeQ10 in progressive supranuclear palsy: a randomized, place-bocontrolled trial. Mov Disord 2008; 23: 942-49.
87. Ferrante KL, Shefner J, Zhang H, et al. Tolerance of high-dose(3,000 mg/day) coenzyme Q10 in ALS. Neurology 2005; 65:1834-36.
88. Kaufmann P, Thompson JLP, Levy G, et al. Phase II trial ofCoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol 2009; 66: 235-44.
89. Feigin A, Kieburtz K, Como P. Assessment of coenzyme Q10 tolerability in Huntington's disease. Mov Disord 1996; 11: 321-23.
90. Raina AK, Zhu X, Shimohama S, Perry G, Smith MA. Tipping the apoptotic balance in Alzheimer's disease: the abortosis concept. Cell Biochem Biophys 2003; 39: 249-55.
91. Gastard MC, Troncoso JC, Koliatsos VE. Caspase activation in the limbic cortex of subjects with early Alzheimer's disease. Ann Neurol 2003; 54: 393-8.
92. Xiao XQ, Zhang HY, Tang XC. Huperzine A attenuates amyloidbeta-peptide fragment 25-35-induced apoptosis in rat cortical neuronsvia inhibiting reactive oxygen species formation and caspase-3activation. J Neurosci Res 2002; 67: 30-6
93. Jordan J, Galindo MF, Miller RJ. Role of calpain- and interleukin-1beta converting enzyme-like proteases in the beta-amyloid-induced death of rat hippo campal neurons in culture. J Neurochem 1997;68: 1612-21.
94. Vosler PS, Brennan CS, Chen J. Calpain-mediated signaling mechanisms in neuronal injury and neuro-degeneration. Mol Neurobiol 2008; 38: 78-100.
95. Polster BM, Basanez G, Etxebarria A, Hardwick JM, Nicholls DG. Calpain I induces cleavage and release of apoptosis-inducing factor from isolated mitochondria. J Biol Chem 2005; 280: 6447-54.
96. Ray SK, Banik NL. Calpain and its involvement in the pathophysiology of CNS injuries and diseases: therapeutic potential of calpaininhibitors for prevention of neurodegeneration. Curr Drug Targets CNS Neurol Disord 2003; 2: 173-89.
97. Siman R, Card JP, Davis LG. Proteolytic processing of beta-amyloid precursor by calpain I. J Neurosci 1990; 10: 2400-11.
98. Camins A, Crespo-Biel N, Junyent F, Verdaguer E, Canudas AM, Pallàs M. Calpains as a target for therapy of neurodegenerative diseases:putative role of lithium. Curr Drug Metab 2009; 10: 433-47.
99. Samantaray S, Ray SK, Banik NL. Calpain as a potential the rapeutic target in Parkinson's disease. CNS Neurol Disord Drug Targets 2008; 7: 305-12.
100. Alvira D, Ferrer I, Gutierrez-Cuesta J, Garcia-Castro B, Pallàs M, Camins A. Activation of the calpain/cdk5/p25 pathway in the girus cinguli in Parkinson's disease. Parkinsonism Relat Disord 2008; 14:309-313.
101. Goñi-Oliver P, Lucas JJ, Avila J, Hernández F. N-terminal cleavage of GSK-3 by calpain: a new form of GSK-3 regulation. J Biol Chem 2007; 282: 22406-13.
102. Crespo-Biel N, Camins A, Gutiérrez-Cuesta J, et al. Regulation ofGSK-3beta by calpain in the 3-nitropropionic acid model. Hippocampus 2010; 20: 962-70.
103. Akashiba H, Ikegaya Y, Nishiyama N, Matsuki N. Differentialinvolvement of cell cycle reactivation between striatal and corticalneurons in cell death induced by 3-nitropropionic acid. J Biol Chem 2008; 283: 6594-606.
104. Ozaki T, Yamashita T, Ishiguro S. Mitochondrial m-calpain plays arole in the release of truncated apoptosis-inducing factor from the mitochondria. Biochim Biophys Acta 2009; 1793: 1848-59.
105. Polster BM, Basañez G, Etxebarria A, Hardwick JM, Nicholls DG. Calpain I induces cleavage and release of apoptosis-inducing factor from isolated mitochondria. J Biol Chem 2005; 280: 6447-54.
106. Schölzke MN, Potrovita I, Subramaniam S, Prinz S, Schwaninger M. Glutamate activates NF-kappaB through calpain in neurons. Eur J Neurosci 2003; 18: 3305-10.
107. Lopes JP, Oliveira CR, Agostinho P. Neurodegeneration in an A beta-induced model of Alzheimer's disease: the role of Cdk5. Aging Cell 2010; 9: 64-77.
108. Rami, A. Ischemic neuronal death in the rat hippocampus: the calpain-calpastatin-caspase hypothesis. Neurobiol Dis 2003; 13:75-88.
109. Ray SK, Hogan EL, Banik NL. Calpain in the pathophysiology ofspinal cord injury: neuroprotection with calpain inhibitors. Brain Res Rev 2003; 42: 169-85.
110. Hernández F, Nido JD, Avila J, Villanueva N. GSK3 inhibitors anddisease. Mini Rev Med Chem 2009; 9: 1024-9.
111. Martinez A, Perez DI. GSK-3 inhibitors: a ray of hope for the treatment of Alzheimer's disease? J Alzheimers Dis 2008; 15: 181-91.
112. Selenica ML, Jensen HS, Larsen AK, et al. Efficacy of small molecule glycogen synthase kinase-3 inhibitors in the postnatal ratmodel of tau hyper phosphorylation. Br J Pharmacol 2007; 152:959-79.
113. Camins A, Verdaguer E, Junyent F, et al. Potential mechanisms involved in the prevention of neurodegenerative diseases by lithium. CNS Neurosci Ther 2009; 15: 333-44.
114. Bhat RV, Budd Haeberlein SL, Avila J. Glycogen synthase kinase3: a drug target for CNS therapies. J Neurochem 2004; 89: 1313-17.
115. Hampel H, Ewers M, Bürger K, et al. Lithium trial in Alzheimer's disease: a randomized, single-blind, placebo-controlled, multicenter10-week study. J Clin Psychiatry 2009; 70: 922-31.
116. Nunes PV, Forlenza OV, Gattaz WF Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. Br J Psychiatry 2007; 190: 359-60.
117. Leyhe T, Eschweiler GW, Stransky E, et al. Increase of BDNF serum concentration in lithium treated patients with early Alzheimer's disease. J Alzheimers Dis 2009; 16: 649-56.
118. Pomara N Lithium treatment in Alzheimer's disease does not promote cognitive enhancement, but may exert long-term neuro-protective effects. Psychopharmacology (Berl) 2009; 205: 169-70.
119. Cohen P, Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat Rev Drug Discov 2004; 3: 479-87.
120. Fornai F, Longone P, Cafaro L, et al. Lithium delays progression ofamyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2008; 105:2052-57.
121. Fornai F, Longone P, Ferrucci M, et al. Autophagy and amyotrophiclateral sclerosis: The multiple roles of lithium. Autophagy 2008; 4: 527-30.
122. Bedlack RS, Maragakis N, Heiman-Patterson T. Lithium may slowprogression of amyotrophic lateral sclerosis, but further study isneeded. Proc Natl Acad Sci USA 2008; 105 E17;
123. Chiò A, Borghero G, Calvo A, et al. LITALS Study Group.Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacyin a dose-finding trial. Neurology 2010; 75: 619-25.
124. Bhat R, Xue Y, Berg S, et al. Structural insights and biologicaleffects of glycogen synthase kinase 3-specific inhibitor ARA014418. J Biol Chem 2003; 278: 45937-45945.
125. Raina AK, Zhu X, Smith MA. Alzheimer's disease and the cellcycle. Acta Neurobiol Exp (Wars) 2004; 64: 107-12.
126. Bowser R, Smith MA. Cell cycle proteins in Alzheimer's disease: plenty of wheels but no cycle. J Alzheim Dis 2002; 4: 249-54.
127. Giovanni A, Wirtz-Brugger F, Keramaris E, Slack R, Park DS.Involvement of cell cycle elements, cyclin-dependent kinases, pRb,and E2F x DP, in B-amyloid-induced neuronal death. J Biol Chem 1999; 274: 19011-16.
128. Copani A, Sortino MA, Caricasole A, et al. Erratic expression ofDNA polymerases by beta-amyloid causes neuronal death. FASEBJ 2002; 16: 2006-8.
129. Copani A, Condorelli F, Canonico PL, Nicoletti F, Sortino MA.Cell cycle progression towards Alzheimer's disease. Funct Neurol 2001; 16: 11-15.
130. Copani A, Uberti D, Sortino MA, Bruno V, Nicoletti F, Memo M.Activation of cell-cycle-associated proteins in neuronal death: amandatory or dispensable path? Trends Neurosci 2001; 24: 25-31.
131. Yang, Y., Geldmacher, D.S., Herrup, K., 2001. DNA replicationprecedes neuronal cell death in Alzheimer's disease. J Neurosci2001; 21: 2661-8.
132. Yang, Y., Mufson, E.J., Herrup, K., 2003. Neuronal cell death ispreceded by cell cycle events at all stages of Alzheimer's disease. JNeurosci 2003; 23: 2557-63.
133. Hou ST, Callaghan D, Fournier MC, Hill I, Kang L, Massie B- Thetranscription factor E2F1 modulates apoptosis of neurons. J Neurochem 2000; 75: 91-100.
134. Hou ST, Cowan E, Walker T, et al. The transcription factor E2F1promotes dopamine-evoked neuronal apoptosis by a mechanismindependent of transcriptional activation. J Neurochem 2001; 78:287-97.
135. Arendt T. Dysregulation of neuronal differentiation and cell cyclecontrol in Alzheimer's disease. J Neural Transm Suppl 2002; 62:77-85.
136. Herrup K, Arendt T. Re-expression of cell cycle proteins inducesneuronal cell death during Alzheimer's disease. J Alzheimers Dis 2002; 4: 243-47.
137. Herrup K, Neve R, Ackerman SL, Copani A. Divide and die: cellcycle events as triggers of nerve cell death. J Neurosci 2004; 24:9232-39.
138. Busser J, Geldmacher DS, Herrup K. Ectopic cell cycle proteinspredict the sites of neuronal cell death in Alzheimer's disease brain. J Neurosci 1998; 18: 2801-07.
139. Jordan-Sciutto KL, Malaiyandi LM, Bowser R. Altered distributionof cell cycle transcriptional regulators during Alzheimer disease. J Neuropathol Exp Neurol 2002; 61: 358-67.
140. Copani A, Sortino MA, Nicoletti F, Giuffrida SA. Alzheimer'sdisease research enters a new cycle: how significant? Neurochem Res 2002; 27: 173-76.
141. Raina AK, Pardo P, Rottkamp CA, Zhu X, Pereira-Smith OM, Smith MA. Neurons in Alzheimer disease emerge from senescence. Mech Ageing Dev 2001; 123: 3-9.
142. Klein JA, Longo-Guess CM, Rossmann MP, et al. The harlequin mouse mutation down regulates apoptosis-inducing factor. Nature 2002; 419: 367-74.
143. Biswas SC, Liu DX, Greene LA. Bim is a direct target of a neuronal E2F-dependent apoptotic pathway. J Neurosci 2005; 25:8349-58.
144. Stevens C, La Thangue NB. The emerging role of E2F-1 in theDNA damage response and checkpoint control. DNA Repair 2004;3: 1071-79.
145. Hershko T, Chaussepied M, Oren M, Ginsberg D. Novel link between E2F and p53: proapoptotic cofactors of p53 are transcriptionally upregulated by E2F. Cell Death Differ 2005; 12: 377-83.
146. Hershko T, Ginsberg D. Up-regulation of Bcl-2 homology 3(BH3)-only proteins by E2F1 mediates apoptosis. J Biol Chem 2004; 279: 8627-34.
147. Verdaguer E, Jimenez A, Canudas AM, et al. Inhibition of cellcycle pathway by flavopiridol promotes survival of cerebellargranule cells after an excitotoxic treatment. J Pharmacol Exp Ther 2004; 308: 609-16.
148. O'Hare MJ, Hou ST, Morris EJ, et al. Induction and modulation ofcerebellar granule neuron death by E2F-1. J Biol Chem 2000; 275:25358-64.
149. Bösel J, Gandor F, Harms C, et al. Neuroprotective effects ofatorvastatin against glutamate-induced excitotoxicity in primarycortical neurones. J Neurochem 2005; 92: 1386-1398.
150. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statinsand the risk of dementia. Lancet 2000; 356: 1627-1631.
151. del Toro D, Xifró X, Pol A, et al. Altered cholesterol homeostasiscontributes to enhanced excitotoxicity in Huntington's disease. JNeuroche m 2010; 115: 153-167.
152. Solomon A, Kåreholt I, Ngandu T, et al. Serum total cholesterol,statins and cognition in non-demented elderly. Neurobiol Aging.2009; 30: 1006-1009.
153. Ma T, Zhao Y, Kwak YD, et al. Statin's excitoprotection is mediatedby sAPP and the subsequent attenuation of calpain-inducedtruncation events, likely via rho-ROCK signaling. J Neurosci 2009;29: 11226-11236.
154. Dolga AM, Granic I, Nijholt IM, et al. Pretreatment with lovastatinprevents N-methyl-D-aspartate-induced neurodegeneration in themagnocellular nucleus basalis and behavioural dysfunction. J AlzheimersDis 2009; 17: 327-336.
155. Ponce J, de la Ossa NP, Hurtado O, et al. Simvastatin reduces theassociation of NMDA receptors to lipid rafts: a cholesterolmediatedeffect in neuroprotection. Stroke 2008; 39: 1269-75.
156. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. ArchNeurol 2000; 57: 1439-43.
157. Zacco A, Togo J, Spence K, Ellis A, Lloyd D, Furlong S, Piser T. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protectcortical neurons from excitotoxicity. J Neurosci 2003; 23:11104-11.
158. Koob AO, Ubhi K, Paulsson JF, et al. Lovastatin amelioratesalpha-synuclein accumulation and oxidation in transgenic mousemodels of alpha-synucleinopathies. Exp Neurol 2010; 221: 267-74.
159. Sørensen HT, Lash TL. Statins and amyotrophic lateral sclerosis--the level of evidence for an association. J Intern Med 2009; 266:520-6.
160. Sellner J, Weber MS, Vollmar P, Mattle HP, Hemmer B, Stüve O. The combination of interferon-beta and HMG-CoA reductase inhibitionin multiple sclerosis: enthusiasm lost too soon? CNS NeurosciTher 2010; 16: 362-73.
161. Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combiningbeta interferon and atorvastatin may increase disease activity inmultiple sclerosis. Neurology 2008; 71: 1390-5.
162. Paul F, Waiczies S, Wuerfel J, et al. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS One 2008;3: e1928.
163. Parkinson Study Group, The safety and tolerability of a mixedlineage kinase inhibitor (CEP-1347) in PD. Neurology 2004; 62:330-2.
164. Troy CM, Rabacchi SA, Xu Z, et al. beta-Amyloid-induced neuronalapoptosis requires c-Jun N-terminal kinase activation. J Neurochem 2001; 77: 157-64.
165. Wang LH, Johnson EM Jr. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2008; 71: 462-73.
166. Waldmeier P, Bozyczko-Coyne D, Williams M, Vaught JL. Recentclinical failures in Parkinson's disease with apoptosis inhibitors underlinethe need for a paradigm shift in drug discovery for neuro-degenerative diseases. Biochem Pharmacol 2006; 72: 1197-206.
167. Apostol BL, Simmons DA, Zuccato C, et al. CEP-1347 reducesmutant huntingtin-associated neurotoxicity and restores BDNF levelsin R6/2 mice. Mol Cell Neurosci 2008, 39: 8-20.
168. Müller GJ, Geist MA, Veng LM, et al. A role for mixed lineagekinases in granule cell apoptosis induced by cytoskeletal disruption. J Neurochem 2006; 96: 1242-52.
169. Yang DD, Kuan CY, Whitmarsh AJ, et al. Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3gene. Nature 1997; 389: 865-70.
170. Kuan CY, Burke RE. Targeting the JNK signaling pathway forstroke and Parkinson's diseases therapy. Curr Drug Targets CNSNeurol Disord 2005; 4: 63-7.
171. Choi WS, Abel G, Klintworth H, Flavell RA, Xia Z. JNK3 mediates paraquat- and rotenone-induced dopaminergic neuron death. J Neuropathol Exp Neurol 2010; 69: 511-20.
172. Pan J, Xiao Q, Sheng CY, et al. Blockade of the translocation andactivation of c-Jun N-terminal kinase 3 (JNK3) attenuates dopaminergic neuronal damage in mouse model of Parkinson's disease. Neurochem Int 2009; 54: 418-25.
173. Borsello T, Forloni G. JNK signalling: a possible target to prevent neurodegeneration. Curr Pharm Des 2007; 13: 1875-86.
174. Repici M, Borsello T. JNK pathway as the rapeutic target to prevent degeneration in the central nervous system. Adv Exp Med Biol 2006; 588: 145-55.
175. Borsello T, Bonny C. Use of cell-permeable peptides to prevent neuronal degeneration. Trends Mol Med 2004; 10: 239-44.
176. Waetzig V, Herdegen T. Context-specific inhibition of JNKs: overcoming the dilemma of protection and damage. Trends Pharmacol Sci 2005; 26: 455-61.
177. Gelderblom M, Eminel S, Herdegen T, Waetzig V. c-Jun N-terminal kinases (JNKs) and the cytoskeleton--functions beyond neurodegeneration. Int J Dev Neurosci 2004; 22: 559-64.
178. Imbimbo BP. The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease. Expert Opin Investig Drugs 2004; 13: 1469-81.
179. Hirohata M, Ono K, Naiki H, Yamada M. Non-steroidal anti-inflammatory drugs have anti-amyloidogenic effects for Alzheimer'sbeta-amyloid fibrils in vitro. Neuropharmacology 2005;49: 1088-99.
180. Patrignani P, Tacconelli S, Sciulli MG, Capone ML. New insightsinto COX-2 biology and inhibition. Brain Res Rev 2005; 48: 352-9.
181. Van Dam D, Coen K, De Deyn PP. Ibuprofen modifies cognitive disease progression in an Alzheimer's mouse model. Psychopharmacol. 2010; 24: 383-8.
182. Pasqualetti P, Bonomini C, Dal Forno G, et al. A randomized controlled study on effects of ibuprofen on cognitive progression ofAlzheimer's disease. Aging Clin Exp Res 2009; 21: 102-10.
183. Galasko DR, Graff-Radford N, May S, et al. Safety, tolerability,pharmacokinetics, and Abeta levels after short-term administrationof R-flurbiprofen in healthy elderly individuals. Alzheimer Dis AssocDisord 2007; 21: 292-9.
184. Wang LH, Besirli CG, Johnson EM Jr. Mixed-lineage kinases: atarget for the prevention of neurodegeneration. Annu Rev Pharmacol Toxicol 2004; 44: 451-74.
185. Hoozemans JJ, O'Banion MK. The role of COX-1 and COX-2 inAlzheimer's disease pathology and the therapeutic potentials ofnon-steroidal anti-inflammatory drugs. Curr Drug Targets CNS Neurol Disord 2005; 4: 307-15.
186. Dinarello CA. Anti-inflammatory Agents: Present and Future. Cell 2010; 140: 935-50.
187. Minghetti L. Cyclooxygenase-2 (COX-2) in inflammatory anddegenerative brain diseases. J Neuropathol Exp Neurol 2004 63:901-10.
188. Chung JH, Seo AY, Chung SW, Kim MK, Leeuwenburgh C, Yu BP, Chung HY. Molecular mechanism of PPAR in the regulationof age-related inflammation. Ageing Res Rev 2008; 7: 126-36.
189. Nicolakakis N, Hamel E. The Nuclear Receptor PPARgamma as aTherapeutic Target for Cerebrovascular and Brain Dysfunction inAlzheimer's Disease. Front Aging Neurosci 2010 May 21; 2.
190. Gold M, Alderton C, Zvartau-Hind M, et al. Rosiglitazone monotherapyin mild-to-moderate alzheimer's disease: results from arandomized, double-blind, placebo-controlled phase III study. Dement Geriatr Cogn Disord 2010; 30: 131-46.
191. Escribano L, Simón AM, Gimeno E, et al. Rosiglitazone rescuesmemory impairment in Alzheimer's transgenic mice: mechanisms
192. Toledo EM, Inestrosa NC. Activation of Wnt signaling by lithiumand rosiglitazone reduced spatial memory impairment and neurodegeneration in brains of an APPswe/PSEN1DeltaE9 mousemodel of Alzheimer's disease. Mol Psychiatry 2010; 15: 272-85.
193. Domercq M, Matute C. Neuroprotection by tetracyclines. Trends Pharmacol Sci 2004; 25: 609-12.
194. Noble W, Garwood C, Stephenson J, Kinsey AM, Hanger DP, Anderton BH. Minocycline reduces the development of abnormaltau species in models of Alzheimer's disease. FASEB J 2009; 23:739-50.
195. Kim HS, Suh YH. Minocycline and neurodegenerative diseases. Behav Brain Res 2009; 196: 168-79.
196. Choi Y, Kim HS, Shin KY, et al. Minocycline attenuates neuronalcell death and improves cognitive impairment in Alzheimer's disease models. Neuro-psychopharmacology 2007; 32: 2393-404.
197. Reynolds N. Revisiting safety of minocycline as neuroprotection in Huntington's disease. Mov Disord 2007; 22: 292.
198. Gordon PH, Moore DH, Miller RG, et al. Western ALS StudyGroup. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007; 6:1045-53.
199. Danysz W, Parsons CG. Neuroprotective potential of ionotropic glutamate receptor antagonists. Neurotox Res 2002; 4: 119-26.
200. Danysz W, Parsons CG. The NMDA receptor antagonist memantineas a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int J Geriatr Psychiatry 2003; 18 (Suppl 1): S23-32.
201. Arundine M., Tymianski M. Molecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity. Cell Calcium 2003;4: 325-37.
202. Wilcock GK. Memantine for the treatment of dementia. Lancet Neurol 2003; 2: 503-05.
203. Molinuevo JL, Llado A, Rami L. Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias. Am J Alzheimers Dis Other Demen 2005; 20: 77-85.
204. Goñi-Oliver P, Avila J, Hernández F. Memantine inhibits calpain-mediated truncation of GSK-3 induced by NMDA: implications inAlzheimer's disease. J Alzheimers Dis 2009; 18: 843-8.
205. Siciliano G, Carlesi C, Pasquali L, et al. Clinical trials for neuroprotectionin ALS. CNS Neurol Disord Drug Targets 2010; 9: 305-313.
206. Zhou ZL, Kher SM, Cai SX, et al. Synthesis and SAR of novel diandtrisubstituted 1,4-dihydroquinoxaline-2,3-diones related to licostinel(Acea 1021) as NMDA/glycine site antagonists. Bioorg Med Chem 2003; 11: 1769-80.
207. Albers GW, Goldstein LB, Hall D, Lesko LM; Aptiganel AcuteStroke Investigators. Aptiganel hydrochloride in acute ischemicstroke: a randomized controlled trial. JAMA 2001; 286: 2673-82.
208. Mandel RJ. CERE-110, an adeno-associated virus-based genedelivery vector expressing human nerve growth factor for thetreatment of Alzheimer's disease. Curr Opin Mol Ther 2010; 12:240-7.
209. Cuello AC, Bruno MA, Allard S, Leon W, Iulita MF. Cholinergicinvolvement in Alzheimer's disease. A link with NGF maturationand degradation. J Mol Neurosci 2010; 40: 230-5.
210. Bishop KM, Hofer EK, Mehta A, et al. Therapeutic potential ofCERE-110 (AAV2-NGF): targeted, stable, and sustained NGF deliveryand trophic activity on rodent basal forebrain cholinergicneurons. Exp Neurol 2008; 211: 574-84.